Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
Authors:
Open Access
- 19 March 2019
- journal article
- research article
- Published by Wiley in Thoracic Cancer
- Vol. 10 (4) , 992-1000
Abstract
Background: It remains unclear why radiation clinically provides a synergistic effect when combined with immune checkpoint inhibitors such as nivolumab. The purpose of our study was to retrospectively evaluate whether the therapeutic efficacy of nivolumab is improved as a result of a history of radiotherapy (RT) in patients with previously treated advanced non‐small cell lung cancer (NSCLC). Methods: From February 2016 to December 2017, 124 consecutive patients were administered nivolumab for pretreated advanced NSCLC. The patients were divided into RT and non‐RT groups. Results: Sixty‐six (53%) of the 124 patients had been administered RT before the initiation of nivolumab, 52 (42%) received extracranial RT, and 40 (32%) were treated with thoracic RT. The median number of nivolumab cycles was 4 (range: 1–43). The overall response rate (ORR) and disease control rate (DCR) of nivolumab in all patients were 28.0% and 58.4%, respectively. The ORR (36.4%) was significantly higher in patients who had received previous RT than in patients who had not received any RT (19%). The therapeutic efficacy of nivolumab was particularly noteworthy in patients with non‐adenocarcinoma and squamous cell carcinoma histology administered extracranial RT, with ORRs of 48.3% and 52.6%, and DCRs of 87.1% and 84.2%, respectively. Conclusion: Previous RT was an independent prognostic marker of favorable prognosis after nivolumab administration and improved the response rate to nivolumab treatment. Previous RT was clinically identified to have a synergistic effect with nivolumab treatment, increasing the response rate and improving the outcome of patients with advanced NSCLC.Keywords
This publication has 18 references indexed in Scilit:
- Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer PatientsAmerican Journal of Clinical Oncology, 2018
- Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibitionAdvances in Radiation Oncology, 2018
- Combining immunotherapy and radiotherapy in lung cancerJournal of Thoracic Disease, 2018
- Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell ResponseInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2018
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trialThe Lancet Oncology, 2017
- Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma CellsFrontiers in Immunology, 2016
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in miceJournal of Clinical Investigation, 2014
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009